Gilead Sciences is a biopharmaceutical company that takes drugs from the idea stage all the way to comprehensive treatments with a focus on the care of patients suffering from life-threatening diseases, principally HIV, hepatitis B and influenza. The company has a research focus on anti-infectives. The company's more than 2,500 employees operate on three continents.
Gilead has 11 products on the market, all tackling potentially life-threatening diseases.
By far the most recognizable, Tamiflu is the world's premier treatment for influenza and in 2005 President Bush asked Congress to spend $1 billion to stockpile Tamiflu in order to hedge against the risk of an outbreak of avian flu.
Almost all of Gilead's drugs target diseases that are extremely life-threatening. Despite a number of current drugs focusing on HIV and AIDS, the company's acquisition of Corus in 2006 points the way to cystic fibrosis as the growth market of the future. In an environment where established companies struggle to replace mature drugs with new treatments as their patents run out, Gilead has succeeded in creating exciting new products.
Subscribe to:
Post Comments (Atom)
0 comments:
Post a Comment